GLP-1 Monitoring
Tailored for users of GLP-1 receptor agonists (Semaglutide, Tirzepatide, Retatrutide). Monitors metabolic improvements, thyroid safety, pancreatic stress, and nutritional status during rapid weight loss.
When to Test
Baseline before starting, then at week 8-12 of titration. Fasted blood draw.
Testing Frequency
Every 3 months during active titration, then every 6 months on a stable maintenance dose.
Markers in This Panel(12)
HbA1c
Glucose MetabolismTracks glycaemic improvement; the primary efficacy marker for GLP-1 therapy.
Ref: 4 – 6 %
Glucose
Glucose MetabolismFasting glucose should improve with GLP-1 use.
Ref: 3.5 – 6 mmol/L
Insulin
Glucose MetabolismGLP-1s improve insulin sensitivity; monitor for improvement.
Ref: 2 – 25 mIU/L
Triglycerides
LipidsGLP-1s significantly reduce triglycerides in most users.
Ref: 0 – 2 mmol/L
HDL
LipidsShould improve as metabolic health improves.
Ref: 1 – 999 mmol/L
LDL
LipidsMay improve modestly; track for cardiovascular benefit.
Ref: 0 – 3.4 mmol/L
TSH
ThyroidGLP-1 agonists carry a precautionary thyroid warning (C-cell tumours in rodents).
Ref: 0.4 – 4 mIU/L
ALT
Liver FunctionGLP-1s can improve fatty liver disease; ALT should decrease.
Ref: 0 – 40 U/L
Creatinine
Kidney FunctionMonitor kidney function during rapid weight loss.
Ref: 60 – 110 umol/L
Albumin
Liver FunctionLow albumin during rapid weight loss suggests inadequate protein intake.
Ref: 35 – 50 g/L
Vitamin B12
OtherGLP-1s may reduce B12 absorption; monitor for deficiency.
Ref: 150 – 750 pmol/L
Vitamin D
OtherNutritional status during caloric restriction.
Ref: 50 – 250 nmol/L
Related Compounds
Track these markers with VitalMetrics
Upload your blood test results, get AI analysis with PED context, and see how your markers trend over time.
Create Free Account